Asset Details
Do you wish to reserve the book?
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
Do you wish to request the book?
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008
Overview
In this phase 2 trial involving 104 patients with relapsing–remitting multiple sclerosis, patients who received rituximab on days 1 and 15 had fewer gadolinium-enhancing lesions on magnetic resonance imaging and fewer relapses during 48 weeks of follow-up than patients who received placebo. Rituximab was associated with more adverse events within 24 hours after the first infusion. The study was too small and short to assess uncommon adverse events or long-term safety.
Patients with relapsing–remitting multiple sclerosis who received rituximab on days 1 and 15 had fewer gadolinium-enhancing lesions on MRI and fewer relapses during 48 weeks of follow-up than patients who received placebo.
Multiple sclerosis, the prototypical inflammatory demyelinating disease of the central nervous system, is second only to trauma as a cause of acquired neurologic disability in young adults.
1
Multiple sclerosis usually begins as a relapsing, episodic disorder (relapsing–remitting multiple sclerosis), evolving into a chronic neurodegenerative condition characterized by progressive neurologic disability.
2
The traditional view of the pathophysiology of multiple sclerosis has held that inflammation is principally mediated by CD4+ type 1 helper T cells. Therapies (e.g., interferon beta and glatiramer acetate) developed on the basis of this theory decrease the relapse rate by approximately one third
3
,
4
but do not fully . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - pharmacology
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Murine-Derived
/ B-Lymphocytes - drug effects
/ Female
/ Humans
/ Immunologic Factors - adverse effects
/ Immunologic Factors - pharmacology
/ Immunologic Factors - therapeutic use
/ Male
/ Multiple Sclerosis, Relapsing-Remitting - drug therapy
/ Multiple Sclerosis, Relapsing-Remitting - immunology
/ Multiple Sclerosis, Relapsing-Remitting - pathology
/ Patients
